Drugs / Pegaferon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01137383 | Dec 2007 → Dec 2009 | hepatitis C virus infection | Tehran University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegaferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01137383 ↗ |
| Known as | pegylated interferon alpha 2a | “Patients were treated with 180 microg pegylated interferon-alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily for 24 or 48 weeks depending on genotype and weight.” PMID 20597564 ↗ Jul 20101“Pegaferon (pegylated interferon alpha 2a) + ribavirin” NCT01137383 ↗ |
| Modality | Protein / enzyme biologic | “40KD pegylated interferon alpha-2a (Pegaferon)” NCT01137383 ↗ |
| Route | Subcutaneous | “pegylated interferon 180 micrograms subcutaneously weekly” NCT01137383 ↗ |